Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Brain zapping trial aims to fix sensory confusion in schizophrenia

NCT ID NCT07632261

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a personalized brain stimulation technique called HD-tACS to help people with schizophrenia better combine information from their senses. The treatment is tailored to each patient's brain activity and targets areas involved in sensory binding. The trial will include 80 participants and aims to reduce perceptual distortions, potentially easing a core symptom of the disorder.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

May 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for control group and patient: * Be aged 18 to 65 years inclusive. * Have read and understood the study information sheet. * Be affiliated with a social security system or be a beneficiary. * Have normal or corrected-to-normal vision (glasses or contact lenses). Exclusion Criteria for control group : * Any contraindication to tACS, e.g., cardiac pacemaker or other devices that could interfere with the electric field. * Any contraindication to MRI, e.g., neurological stimulator, pacemaker, cardiac defibrillator, cardiac or vascular prosthesis, intracranial clips or clamps, cerebrospinal fluid shunt, metallic fragments in the eyes, cochlear implants, severe claustrophobia. (A standardized MRI screening questionnaire will be provided.) * Pregnancy or breastfeeding. (Pregnancy status will be verified with a test on the day of the exam.) * Legal incapacity (under guardianship, conservatorship, or judicial/administrative detention) or inability to provide informed consent. * Major psychiatric disorders (excluding tobacco use disorder). * Neurological disorders. * Severe somatic disorders that could interfere with participation. * Uncorrected visual impairments. * Recent consumption of substances likely to alter brain activity (alcohol, drugs, etc.). * Presence of any psychiatric disorder. * Under legal protection (guardianship or conservatorship). Exclusion Criteria - Patient Group A potential patient participant will be excluded if they have: * Any contraindication to tACS, e.g., cardiac pacemaker or other devices that could interfere with the electric field. * Any contraindication to MRI, e.g., neurological stimulator, pacemaker, cardiac defibrillator, cardiac or vascular prosthesis, intracranial clips or clamps, cerebrospinal fluid shunt, metallic fragments in the eyes, cochlear implants, severe claustrophobia. (A standardized MRI screening questionnaire will be provided.) * Pregnancy or breastfeeding. (Pregnancy status will be verified with a test on the day of the exam.) * Legal incapacity (under guardianship, conservatorship, or judicial/administrative detention) or inability to provide informed consent. * Major psychiatric disorders other than schizophrenia (excluding tobacco use disorder). * Neurological disorders. * Severe somatic disorders that could interfere with participation. * Uncorrected visual impairments. * Recent consumption of substances likely to alter brain activity (alcohol, drugs, etc.).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Schizophrenia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.